@eddyquekett's testosterone gel vs injection claims checked

What did @eddyquekett actually say?

The creator made three distinct claims worth examining. First, that testosterone gel is safer for people with clotting disorders because it avoids "a big testosterone spike." Second, that injections have a better absorption rate than gel but that dosing compensates for this. Third, that early changes on injections might come from that same spike "kickstarting" the body, but that outcomes at six months or a year might be similar between delivery methods. Credit where it's due: they flagged their own uncertainty and asked viewers to correct them. That's not how most TikTok health content works.

They were also careful to frame this as personal experience, not a protocol for others. That framing matters a lot when you're talking about a controlled substance and a community that often self-educates out of necessity.

Does the science back this up?

On the clotting risk point, yes, mostly. The spike concern is real and documented. On the absorption and dosing compensation claim, also largely correct. On the "same results at six months" hypothesis, the evidence is thinner and more complicated than a quick TikTok allows.

Testosterone injections, particularly cypionate and enanthate, do produce supraphysiologic peaks in the first 24-72 hours post-injection, followed by a trough before the next dose. Phat et al. (2017, Journal of Clinical Endocrinology and Metabolism) confirmed that weekly injections produce significantly higher peak-to-trough variability than transdermal gels. This variability is not just a comfort issue. Hematocrit rises more sharply with injection-based testosterone, and elevated hematocrit is a recognized risk factor for venous thromboembolism. For someone with a pre-existing clotting disorder, gel's flatter pharmacokinetic profile is a clinically reasonable choice. A 2019 review by Grech et al. in the European Journal of Endocrinology confirmed that transdermal testosterone maintains more stable serum levels and is associated with lower hematocrit elevation compared to depot injections.

What did they get wrong (or right)?

The absorption framing is slightly off, but not dangerously so. They said injections have "a better absorption rate" because you're "rejecting it into your body." The correct term is bioavailability, not absorption rate, and the mechanism is more specific: intramuscular or subcutaneous injections bypass first-pass metabolism entirely and avoid the inconsistent dermal uptake that makes gel dosing tricky. Transdermal testosterone bioavailability is estimated at 9-14% in most pharmacokinetic studies, while injectable forms approach near-complete bioavailability.

The "same changes at six months" hypothesis is where they wisely hedged. The honest answer is that we don't have high-quality head-to-head RCT data comparing masculinization timelines in transgender men across delivery methods, controlling for equivalent serum testosterone levels. What we do know from the Endocrine Society guidelines (Hembree et al., 2017, Journal of Clinical Endocrinology and Metabolism) is that target serum levels, not delivery method, are the primary driver of feminization or masculinization changes. If gel achieves equivalent steady-state testosterone levels, outcomes should be comparable over time. The spike hypothesis for faster early changes is plausible but unconfirmed in the transmasculine context specifically.

What should you actually know?

The delivery method debate often generates more heat than it deserves. The goal is achieving and maintaining target serum testosterone levels, and both gel and injections can do that when dosed correctly and monitored by a clinician. The real practical differences come down to adherence, skin absorption variability, transfer risk with gel, needle aversion, and, as this creator correctly identified, individual medical history.

The clotting disorder point is genuinely important and underrepresented in community discussions. Conditions like Factor V Leiden mutation, antiphospholipid syndrome, or a history of DVT are legitimate reasons a prescriber might choose transdermal over injectable testosterone. This isn't a fringe concern. A 2016 FDA drug safety communication flagged VTE risk with testosterone therapy broadly, though the data was primarily from cisgender men on TRT.

• Gel transfer to partners or children through skin contact is a real safety issue. Hands should be washed and application sites covered.
• Gel absorption varies significantly by application site, skin hydration, and individual factors. Some people simply do not absorb it well enough to reach therapeutic levels.
• "Compensated for in dosage" is true in principle, but finding the right gel dose often takes more titration than injections.
• If you have any clotting history or family history of clotting disorders, tell your provider before starting testosterone in any form.

Bottom line

This is one of the more medically literate testosterone TikToks circulating in transmasc spaces right now. The creator got the clotting risk reasoning essentially right, acknowledged the limits of their knowledge, and did not tell anyone what dose to take or claim one method is universally superior. The "faster changes from the spike" theory is speculative but not wrong. Where they stumbled, using "absorption rate" loosely and leaving the six-month equivalence claim hanging without evidence, they also had the self-awareness to flag as uncertain. That's a low bar, but in this content category, it clears it.